StockNews.com Initiates Coverage on Cytosorbents (NASDAQ:CTSO)

Research analysts at StockNews.com began coverage on shares of Cytosorbents (NASDAQ:CTSO - Get Free Report) in a research report issued to clients and investors on Monday. The brokerage set a "hold" rating on the medical research company's stock.

Other equities analysts also recently issued research reports about the company. D. Boral Capital restated a "buy" rating and issued a $10.00 target price on shares of Cytosorbents in a research note on Friday, May 2nd. HC Wainwright reiterated a "neutral" rating and set a $1.00 target price on shares of Cytosorbents in a research note on Thursday, April 3rd. Two research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $4.67.

Cytosorbents Stock Up 1.1 %

NASDAQ:CTSO traded up $0.01 on Monday, hitting $0.88. The stock had a trading volume of 18,602 shares, compared to its average volume of 204,624. The company has a quick ratio of 1.58, a current ratio of 1.97 and a debt-to-equity ratio of 1.06. Cytosorbents has a 52 week low of $0.70 and a 52 week high of $1.61. The business's fifty day moving average is $1.02 and its 200 day moving average is $1.00. The company has a market cap of $55.10 million, a PE ratio of -2.44 and a beta of 1.17.

Cytosorbents (NASDAQ:CTSO - Get Free Report) last posted its quarterly earnings results on Monday, March 31st. The medical research company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.04. The business had revenue of $9.20 million during the quarter, compared to the consensus estimate of $10.09 million. Cytosorbents had a negative net margin of 49.47% and a negative return on equity of 118.54%. On average, equities research analysts expect that Cytosorbents will post -0.3 EPS for the current fiscal year.

Institutional Investors Weigh In On Cytosorbents

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Avenir Corp raised its position in shares of Cytosorbents by 4.0% in the fourth quarter. Avenir Corp now owns 3,093,946 shares of the medical research company's stock valued at $2,815,000 after purchasing an additional 118,387 shares during the period. Skylands Capital LLC lifted its position in shares of Cytosorbents by 7.9% during the first quarter. Skylands Capital LLC now owns 3,002,702 shares of the medical research company's stock worth $3,003,000 after acquiring an additional 221,080 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Cytosorbents by 7.5% in the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company's stock worth $701,000 after acquiring an additional 32,415 shares during the period. Raymond James Financial Inc. purchased a new position in shares of Cytosorbents in the fourth quarter valued at $99,000. Finally, Northern Trust Corp raised its stake in shares of Cytosorbents by 22.3% during the 4th quarter. Northern Trust Corp now owns 91,560 shares of the medical research company's stock valued at $83,000 after purchasing an additional 16,701 shares during the period. 32.87% of the stock is currently owned by institutional investors.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.